tuberculosi
caus
seriou
health
problem
world
popul
antigen
peptid
select
pathogenspecif
cytotox
lymphocyt
ctl
present
major
histocompat
complex
mhc
human
leukocyt
antigen
hla
human
molecul
hlaa
restrict
respons
may
interest
vaccin
develop
understand
cellular
immun
seri
peptid
deriv
cultur
filtrat
protein
kda
earli
secretori
antigen
target
mycobacterium
tuberculosi
mtb
screen
ctl
epitop
restrict
human
leukocyt
antigen
common
hla
allel
asian
peopl
identifi
studi
studi
panel
peptid
identifi
bind
motif
molecul
antigen
candid
peptid
assess
vitro
refold
test
enzymelink
immunospot
elispot
assay
tetram
stain
determin
capac
stimul
ctl
peripher
blood
mononuclear
cell
pbmc
tb
patient
report
one
novel
candid
peptid
posit
mtb
could
induc
peptidespecif
ctl
pbmc
patient
patient
healthi
control
identifi
epitop
weak
binder
molecul
mini
mhc
refold
assay
sinc
peptid
present
common
hla
class
molecul
may
use
immunotherapi
mtb
infect
vaccin
develop
larg
popul
mtbinfect
patient
current
tuberculosi
remain
one
top
three
fatal
infecti
diseas
togeth
acquir
immun
defici
syndrom
aid
malaria
china
estim
million
popul
individu
latent
infect
mycobacterium
tuberculosi
mtb
million
smearposit
cultureposit
pulmonari
tuberculosi
tb
patient
although
mechan
protect
tuberculosi
complet
understood
mani
line
evid
shown
antigenspecif
cytotox
lymphocyt
ctl
might
effect
limit
spread
mtb
clear
mtb
infect
control
mycobacteri
growth
mhc
class
irestrict
ctl
expect
recogn
react
target
epitop
present
antigen
present
cell
cours
infect
moreov
cytokin
interferon
gamma
ifng
produc
cell
critic
role
protect
immunolog
respons
primari
infect
howev
antigen
specif
human
cell
respons
known
strongli
disciplin
hla
polymorph
immunogen
potenti
candid
vaccin
need
elucid
context
major
hla
polymorph
abbrevi
mtb
mycobacterium
tuberculosi
ctl
cytotox
lymphocyt
ifng
interferon
gamma
pbmc
peripher
blood
mononuclear
cell
cultur
filtrat
protein
kda
earli
secretori
antigen
target
mhc
major
histocompat
complex
hla
human
leukocyt
antigen
tb
tuberculosi
microglobulin
sfc
spotform
cell
hplc
high
perform
liquid
chromatographi
pha
phytohaemagglutinin
recombin
human
recombin
human
afb
acidfast
bacilli
pe
phycoerythrin
bcg
bacillu
ltbi
latent
tb
infect
therefor
identif
specif
ctl
epitop
context
major
hla
allel
remain
critic
step
understand
mycobacteri
control
mechan
evalu
tb
vaccin
antigen
tb
seem
larg
depend
upon
two
import
secret
protein
earli
secretori
antigen
target
cultur
filtrat
protein
previous
demonstr
abl
stimul
cell
produc
ifng
display
cytolyt
ctl
activ
human
infect
mtb
suggest
potenti
candid
applic
antituberculosi
subunit
vaccin
seri
epitop
cell
restrict
certain
mhc
molecul
identifi
accord
report
frequenc
hla
allel
human
one
common
hlaa
allel
worldwid
especi
asian
popul
nevertheless
rel
epitop
present
molecul
defin
human
cell
mtb
infect
present
studi
adapt
approach
util
panel
synthet
peptid
contain
motif
identif
ctl
epitop
protein
seven
tb
patient
no
two
healthi
control
examin
induct
tbspecif
ctl
tabl
patient
recruit
nanj
chest
hospit
peopl
hospit
luhe
nanj
diagnosi
tuberculosi
confirm
case
one
diagnost
standard
develop
ministri
health
peopl
republ
china
two
posit
acidfast
bacilli
afb
smear
posit
sputum
cultur
tuberculosi
chest
xray
show
radiograph
abnorm
characterist
pulmonari
tuberculosi
least
two
sputum
specimen
neg
afb
cultur
chest
xray
show
sign
activ
pulmonari
tuberculosi
accompani
symptom
cough
cough
bloodting
sputum
cough
blood
chest
distress
chest
pain
tired
four
patient
no
patient
no
two
healthi
control
histori
tuberculosi
histori
contact
patient
tuberculosi
patient
hiv
neg
tb
patient
group
includ
three
women
four
men
purpos
perform
studi
fulli
explain
particip
nanj
chest
hospit
peopl
hospit
luhe
collect
peripher
blood
mononuclear
cell
pbmc
sampl
author
hospit
ethic
review
committe
fifteen
millilit
peripher
blood
obtain
subject
pbmc
prepar
ficolleconray
densiti
gradient
centrifug
sampl
cryopreserv
liquid
nitrogen
use
experi
express
hlaa
molecul
pbmc
determin
follow
hla
type
subject
done
use
fresh
pbmc
dna
extract
pbmc
use
relaxgen
blood
tiangen
beij
china
low
resolut
hla
type
perform
use
pcr
sequencespecif
primer
protran
germani
mhc
allel
identifi
version
score
virtual
sequenc
softwar
result
hla
type
subject
list
tabl
peptid
purchas
sb
genetech
beij
china
precis
inform
regard
peptid
provid
tabl
puriti
peptid
use
determin
high
perform
liquid
chromatographi
hplc
peptid
dissolv
dimethylsulfoxid
sigma
st
loui
mo
usa
concentr
mgml
store
c
human
recombin
human
recombin
purchas
r
system
minneapoli
mn
usa
refold
perform
describ
previous
minor
modif
briefli
heavi
chain
express
prokaryot
express
system
heavi
chain
peptid
subsequ
ad
refold
buffer
mm
trishcl
mm
largininehcl
mm
sodium
edta
mm
oxid
glutathion
mm
reduc
glutathion
mm
pmsf
mgml
pepstatin
mgml
leupeptin
stir
c
h
solubl
refold
portion
concentr
purifi
superdex
gel
filtrat
chromatographi
ge
healthcar
bioscienc
ab
indic
correctli
refold
peptideehla
complex
subject
tb
patient
subject
tb
patient
subject
healthi
control
predict
hlaa
peptid
tb
epitop
plate
membran
precoat
mgml
antiifng
mab
epigen
beij
china
overnight
c
pbmc
cell
per
well
ad
duplic
well
candid
peptid
use
concentr
mgml
stimul
effector
cell
posit
control
mgml
phytohaemagglutinin
pha
also
ad
pair
elispot
well
tbstimul
provid
epigen
incub
co
medium
discard
well
wash
prior
addit
antihuman
biotinyl
interferong
epigen
beij
china
mgml
per
well
plate
incub
room
temperatur
h
wash
follow
addit
streptavidinealkalin
phosphatas
chromogen
substrat
nbtbcip
epigen
beij
china
develop
sfc
count
use
elispot
reader
autoimmun
diagnostika
gmbh
strasberg
germani
typic
neg
control
less
spot
case
posit
reactiv
sampl
least
spot
neg
control
neg
control
spot
respons
consid
posit
well
contain
two
time
mean
sfc
neg
control
pbmc
separ
whole
blood
two
one
tb
patient
well
one
healthi
control
pbmc
ml
cultur
peptid
concentr
mm
ml
medium
consist
rpmi
supplement
fetal
calf
serum
amino
acid
pyruv
antibiot
ngml
unitsml
eurocetu
amsterdam
netherland
tissu
cultur
plate
half
medium
chang
everi
day
supplement
final
concentr
uml
day
cell
harvest
test
presenc
peptidespecif
cell
ifnreleas
elispot
assay
tetramer
complexepeptid
molecul
contain
candid
peptid
construct
use
previous
describ
method
cell
incub
c
min
pelabel
tetramer
complex
wash
pb
prior
incub
c
fitclabel
mab
ebiosci
san
diego
ca
usa
sampl
detect
flow
cytometri
guava
easycyt
tetramerposit
cell
gate
lymphocyt
count
epitopespecif
ctl
statist
analysi
perform
use
unpair
twotail
student
ttest
compar
cytokin
releas
differ
consid
signific
p
epitop
identifi
ex
vivo
color
ifng
elispot
assay
tetram
stain
freshli
isol
pbmc
identifi
peptid
recogn
tbspecif
ctl
context
molecul
ifng
elispot
assay
perform
use
freshli
isol
pbmc
pbmc
sampl
obtain
donor
recov
tb
type
express
sampl
donor
candid
peptid
test
capac
stimul
ifnsecret
pbmc
four
tb
donor
ex
vivo
induct
ifnsecret
reveal
direct
elispot
assay
freshli
isol
pbmc
shown
fig
significantli
elicit
specif
ifnproduc
ctl
pbmc
tb
donor
compar
neg
control
ae
vs
ae
spotform
cell
sfc
pbmc
p
cell
respons
observ
pbmc
stimul
test
peptid
except
ae
vs
ae
howev
statist
differ
ifnproduc
cell
number
group
neg
control
well
tb
donor
healthi
donor
similar
level
sfc
group
neg
control
consequ
tetram
prepar
use
confirm
exist
ctl
fresh
pbmc
healthi
donor
tb
donor
tb
donor
stain
tetram
proport
cell
detect
flow
cytometri
result
show
percentag
ctl
detect
tb
donor
averag
three
time
higher
pbmc
test
healthi
control
tb
donor
fig
pbmc
stimul
day
presenc
peptid
uml
recombin
human
ngml
recombin
human
induct
ifnsecret
reveal
elispot
assay
presenc
adopt
assay
test
mani
sampl
simultan
plate
use
rel
small
number
ctl
shown
tabl
polyclon
tbspecif
cell
establish
pbmc
tb
donor
produc
signific
number
ifng
spot
incub
peptid
respond
gener
control
produc
small
number
spot
peptid
significantli
elicit
specif
ifnproduc
ctl
pbmc
tb
donor
compar
healthi
control
tb
donor
test
bind
affin
candid
peptid
molecul
adopt
peptideinduc
stabil
assay
heavi
chain
light
chain
vitro
predict
peptid
could
refold
h
chain
molecul
vari
avid
fig
among
stronger
avid
compar
posit
control
peptid
peptid
higher
avid
lower
bind
effici
molecul
peptid
qfkdnvill
act
posit
control
show
high
bind
capac
molecul
heavi
chain
light
chain
could
form
mhc
complex
presenc
peptid
gilgfvftl
tuberculosi
lead
caus
death
singl
bacteri
speci
sever
impact
global
health
vaccin
mycobacterium
bovi
bcg
bacillu
reduc
sever
tuberculosi
children
howev
limit
evid
efficaci
bcg
vaccin
appli
adult
furthermor
vaccin
may
caus
sever
diseas
immunocompromis
patient
infect
hiv
suffer
tumor
cell
play
vital
role
fight
tuberculosi
proven
cell
essenti
immun
cell
indispens
part
antibacteri
immun
consid
bcg
power
stimul
cell
poor
stimul
cell
work
focu
elicit
potent
cell
cell
respons
achiev
better
immun
studi
use
approach
start
comput
motif
predict
predict
bind
affin
comput
algorithm
report
valu
panel
peptid
deriv
tb
protein
select
screen
base
comput
algorithm
peptid
could
bind
h
l
chain
molecul
variou
avid
vitro
determin
dilut
refold
candid
peptid
previous
test
capac
bind
molecul
cell
surfac
observ
affin
peptid
entir
consist
measur
two
assay
peptid
could
refold
heavi
chain
light
chain
howev
bind
affin
observ
three
peptid
cell
surfac
stabil
assay
suggest
factor
temperatur
conform
heavi
chain
mhc
class
may
affect
format
mhci
molecular
complex
may
account
discrep
verifi
result
assay
pbmc
tb
donor
determin
cellspecif
respons
candid
peptid
peptid
ctl
tb
donor
significantli
detect
stimul
elispot
assay
tetram
stain
studi
demonstr
although
vitro
refold
effect
approach
identifi
hla
class
irestrict
cell
epitop
peptid
refold
capac
correspond
hla
allel
exampl
may
react
well
cell
assay
elispot
assay
tetram
stain
peptid
present
lower
bind
capac
target
hla
allel
exampl
may
distinctli
induc
peptidespecif
ctl
assum
potenti
cell
epitop
may
miss
use
refold
test
sole
identifi
peptid
may
peptid
bind
hla
rel
low
affin
still
bind
tcr
high
affin
therefor
establish
immunodomin
tbspecif
cell
epitop
exist
would
requir
screen
ifng
elispot
assay
tetram
stain
studi
demonstr
presenc
ctl
specif
tuberculosi
protein
antigen
infect
individu
differ
level
epitopespecif
cell
may
found
subject
activ
mtb
infect
contain
infect
ltbi
individu
activ
diseas
antigen
load
high
larg
number
cell
inde
sequest
lung
peripher
blood
result
obtain
pbmc
human
may
necessarili
reflect
local
immun
respons
infect
ctl
epitop
discov
could
investig
subject
latent
tb
either
elev
cell
frequenc
could
major
forc
contain
infect
consequ
persist
pathogen
insid
macrophag
long
time
conclus
provid
evid
peptid
qwnfagieaa
may
novel
natur
process
ctl
epitop
adequ
sensit
target
recognit
ctl
mtbinfect
patient
carri
peptid
weak
binder
molecul
light
chain
refold
assay
show
medium
affin
mhc
stabil
assay
sequenc
encompass
residu
qwnfagieaa
locat
ntermin
side
protein
whose
correspond
gene
locat
dna
region
delet
attenu
tuberculosi
vaccin
bcg
well
known
domin
target
cellmedi
immun
frequent
recogn
earli
tb
infect
regard
ctl
epitop
identifi
studi
may
use
enhanc
ctl
activ
specif
mtb
protein
prevent
spread
mycobacteria
larg
popul
mtbinfect
patient
none
author
conflict
interest
relat
studi
